| Nov 15 |
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
|
| Nov 14 |
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
|
| Nov 14 |
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 13 |
Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ...
|
| Nov 12 |
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
|
| Nov 12 |
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 12 |
Mirum Pharmaceuticals GAAP EPS of -$0.30 beats by $0.16, revenue of $90.38M beats by $8.39M
|
| Nov 12 |
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
